Live-Attenuated Tularemia Vaccine
|
| Inventor: Jean A. Celli and Catharine M. Bosio (NIAID) | Record Date: 10/29/2009 |
| Last Updated: 10/29/2009 |
Abstract: |
| The invention provides compositions and methods of use for a modified strain of Francisella tularensis, the causative agent of tularemia, a category A biodefense agent (NIAID classification). Currently, no vaccines are available, and the only approved therapeutics for tularemia are antibiotics that are only effective if delivered early in the infection. The subject invention defines and characterizes mutations in Francisella tularensis that result in attenuated bacteria capable of inducing strong protective immune responses. Thus, these stable mutant strains could be used as efficient live vaccines against tularemia. Advantages: -- Live-attenuated bacteria can be easily produced through recombinant technologies -- Live-attenuated vaccines do no require adjuvants -- Immune response to live-attenuated vaccines lasts for years and does not require booster Development Status: In vitro and in vivo data available |
Applications: |
| Live-attenuated vaccines against Francisella tularensis |
Patent:
U.S. Provisional Application No. 61/156,173 filed 27 Feb 2009 |
License:
Available for licensing. Collaborative Research Opportunity: The NIAID Office of Technology Development is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize live vaccine strains of Francisella tularensis with defined mutations. Please contact Rosemary Walsh at 301-496-2644 for more information. |
Address:
National Institutes of Health
Office of Technology Transfer
6011 Executive Boulevard, Suite 325
Rockville, MD 20852
USA
Phone: 301-435-5606
Fax: 301-402-0220 | |
E-mail:
HuS@mail.nih.gov
URL:
http://www.ott.nih.gov
|
KE Subscription:
